Soliman AS, Kleer CG, Mrad K, Karkouri M, Omar S, Khaled HM, Benider AL, Ayed FB, Eissa SS, Eissa MS, McSpadden EJ, Lo AC, Toy K, Kantor ED, Xiao Q, Hampton C, Merajver SD.
Inflammatory breast cancer in North Africa: Comparison of clinical and molecular epidemiologic characteristics of patients from Egypt, Tunisia, and Morocco.
Breast Dis. 2012 Sep 21.

Rosenthal DT, Zhang J, Bao L, Zhu L, Wu Z, Toy K, Kleer CG, Merajver SD.
RhoC Impacts the Metastatic Potential and Abundance of Breast Cancer Stem Cells.
PLoS One. 2012;7(7):e40979. Epub 2012 Jul 23.

Sepulchre JA, Merajver SD, Ventura AC.
Retroactive signaling in short signaling pathways.
PLoS One. 2012;7(7):e40806. Epub 2012 Jul 26.

Schneider BJ, Lee JS, Hayman JA, Chang AC, Orringer MB, Pickens A, Pan CC, Merajver SD, Urba SG.
Pre-operative chemoradiation followed by post-operative adjuvant therapy with tetrathiomolybdate, a novel copper chelator, for patients with resectable esophageal cancer.
Invest New Drugs. 2012 Jul 31.

Katapodi MC, Northouse LL, Milliron KJ, Liu G, Merajver SD.
Individual and family characteristics associated with BRCA1/2 genetic testing in high-risk families.
Psychooncology. 2012 Jul 24. doi: 10.1002/pon.3139.

Schlichting JA, Soliman AS, Schairer C, Schottenfeld D, Merajver SD.
Inflammatory and non-inflammatory breast cancer survival by socioeconomic position in the Surveillance, Epidemiology, and End Results database, 1990-2008.
Breast Cancer Res Treat. 2012 Aug;134(3):1257-68. Epub 2012 Jun 26.

O'Brien KS, Soliman AS, Annan K, Lartey RN, Awuah B, Merajver SD.
Traditional herbalists and cancer management in kumasi, ghana.
J Cancer Educ. 2012 Jun;27(3):573-9.

Rosenthal DT, Merajver SD.
Rethinking the war on cancer: multidisciplinary collaborations between biologists and physical scientists.
Future Oncol. 2012 Apr;8(4):339-41.

Wynn ML, Merajver SD, Schnell S.
Unraveling the complex regulatory relationships between metabolism and signal transduction in cancer.
Adv Exp Med Biol. 2012;736:179-89.

Uddin N, Fateem E, Hablas A, Seifeldin IA, Brown E, Merajver SD, Soliman AS.
Public and professional educational needs for downstaging breast cancer in egypt.
J Cancer Educ. 2012 Mar;27(1):149-55.

Uddin N, Fateem E, Hablas A, Seifeldin IA, Brown E, Merajver SD, Soliman AS.
Erratum to: Public and Professional Educational Needs for Downstaging Breast Cancer in Egypt.
J Cancer Educ. 2012 Jan 13.

Wynn ML, Merajver SD, Schnell S.
Unraveling the complex regulatory relationships between metabolism and signal transduction in cancer.
Adv Exp Med Biol. 2012;736:179-89.

Schlichting JA, Soliman AS, Schairer C, Banerjee M, Rozek LS, Schottenfeld D, Harford JB, Merajver SD.
Association of inflammatory and noninflammatory breast cancer with socioeconomic characteristics in the Surveillance, Epidemiology, and End Results database, 2000-2007.
Cancer Epidemiol Biomarkers Prev. 2012 Jan;21(1):155-65. Epub 2011 Oct 25.


Rosenthal DT, Iyer H, Escudero S, Bao L, Wu Z, Ventura AC, Kleer CG, Arruda EM, Garikipati K, Merajver SD.
p38γ promotes breast cancer cell motility and metastasis through regulation of RhoC GTPase, cytoskeletal architecture, and a novel leading edge behavior.
Cancer Res. 2011 Oct 15;71(20):6338-49. Epub 2011 Aug 23.

Merajver SD, Balkrishnan R.
Making the case for integrated assessments of the biological, social, and system determinants of treatment for breast cancer to understand and improve outcomes in patients everywhere.
Curr Med Res Opin. 2011 Oct 14.

Jiang P, Ventura AC, Sontag ED, Merajver SD, Ninfa AJ, Del Vecchio D.
Load-induced modulation of signal transduction networks.
Sci Signal. 2011 Oct 11;4(194):ra67. doi: 10.1126/scisignal.2002152.

Wynn ML, Ventura AC, Sepulchre JA, García HJ, Merajver SD.
Kinase inhibitors can produce off-target effects and activate linked pathways by retroactivity.
BMC Syst Biol. 2011 Oct 4;5:156.

Gilbert SF, Soliman AS, Iniesta M, Eissa M, Hablas A, Seifeldin IA, Strahley A, Banerjee M, Merajver SD.
Androgen receptor polyglutamine tract length in Egyptian male breast cancer patients.
Breast Cancer Res Treat. 2011 Sep;129(2):575-81. doi: 10.1007/s10549-011-1510-6. Epub 2011 Apr 20.

Spencer B, Banerjee M, Omar S, Khaled H, Anwar N, Zaghloul MS, Eissa S, Kleer CG, Dey S, Merajver SD, Soliman AS.
Survival of inflammatory breast cancer patients compared to non-inflammatory breast cancer patients in Egypt.
Breast J. 2011 Sep-Oct;17(5):545-7. doi: 10.1111/j.1524-4741.2011.01146.x. Epub 2011 Aug 9.

Katapodi MC, Northouse L, Pierce P, Milliron KJ, Liu G, Merajver SD.
Differences between women who pursued genetic testing for hereditary breast and ovarian cancer and their at-risk relatives who did not.
Oncol Nurs Forum. 2011 Sep;38(5):572-81.

Alford SH, Toy K, Merajver SD, Kleer CG.
Increased risk for distant metastasis in patients with familial early-stage breast cancer and high EZH2 expression.
Breast Cancer Res Treat. 2011 May 26.

Ossareh HR, Ventura AC, Merajver SD, Del Vecchio D.
Long signaling cascades tend to attenuate retroactivity.
Biophys J. 2011 Apr 6;100(7):1617-26.

Gonzalez ME, DuPrie ML, Krueger H, Merajver SD, Ventura AC, Toy KA, Kleer CG.
Histone methyltransferase EZH2 induces Akt-dependent genomic instability and BRCA1 inhibition in breast cancer.
Cancer Res. 2011 Mar 15;71(6):2360-70.

Dawood S, Merajver SD, Viens P, Vermeulen PB, Swain SM, Buchholz TA, Dirix LY, Levine PH, Lucci A, Krishnamurthy S, Robertson FM, Woodward WA, Yang WT, Ueno NT, Cristofanilli M.
International expert panel on inflammatory breast cancer: consensus statement for standardized diagnosis and treatment.
Ann Oncol. 2011 Mar;22(3):515-23. Epub 2010 Jul 5.

Bosch-Barrera J, Merajver SD, Menéndez JA, Van Poznak C.
Direct antitumour activity of zoledronic acid: preclinical and clinical data.
Clin Transl Oncol. 2011 Mar;13(3):148-55. Review.

Gilbert SF, Soliman AS, Karkouri M, Quinlan-Davidson M, Strahley A, Eissa M, Dey S, Hablas A, Seifeldin IA, Ramadan M, Benjaafar N, Toy K, Merajver SD.
Clinical profile, BRCA2 expression, and the androgen receptor CAG repeat region in Egyptian and Moroccan male breast cancer patients.
Breast Dis. 2011 Jan 1;33(1):17-26.


Varedi K SM, Ventura AC, Merajver SD, Lin XN.
Multisite phosphorylation provides an effective and flexible mechanism for switch-like protein degradation.
PLoS One. 2010 Dec 13;5(12):e14029.

Iniesta MD, Gorin MA, Chien LC, Thomas SM, Milliron KJ, Douglas JA, Merajver SD.
Absence of CHEK2*1100delC mutation in families with hereditary breast cancer in North America.
Cancer Genet Cytogenet. 2010 Oct 15;202(2):136-40.

Dey S, Soliman AS, Hablas A, Seifeldein IA, Ismail K, Ramadan M, El-Hamzawy H, Wilson ML, Banerjee M, Boffetta P, Harford J, Merajver SD.
Urban-rural differences in breast cancer incidence in Egypt (1999-2006).
Breast. 2010 Oct;19(5):417-23. Epub 2010 May 8.

Bevers TB, Armstrong DK, Arun B, Carlson RW, Cowan KH, Daly MB, Fleming I, Garber JE, Gemignani M, Gradishar WJ, Krontiras H, Kulkarni S, Laronga C, Loftus L, Macdonald DJ, Mahoney MC, Merajver SD, Meszoely I, Newman L, Pritchard E, Seewaldt V, Sellin RV, Shapiro CL, Ward JH.
Breast cancer risk reduction.
J Natl Compr Canc Netw. 2010 Oct;8(10):1112-46.

Kumar P, Yadav A, Patel SN, Islam M, Pan Q, Merajver SD, Teknos TN.
Tetrathiomolybdate inhibits head and neck cancer metastasis by decreasing tumor cell motility, invasiveness and by promoting tumor cell anoikis.
Mol Cancer. 2010 Aug 3;9:206.

Pierce LJ, Phillips KA, Griffith KA, Buys S, Gaffney DK, Moran MS, Haffty BG, Ben-David M, Kaufman B, Garber JE, Merajver SD, Balmaña J, Meirovitz A, Domchek SM.
Local therapy in BRCA1 and BRCA2 mutation carriers with operable breast cancer: comparison of breast conservation and mastectomy.
Breast Cancer Res Treat. 2010 Jun;121(2):389-98. Epub 2010 Apr 22.

Wu M, Wu ZF, Rosenthal DT, Rhee EM, Merajver SD.
Characterization of the roles of RHOC and RHOA GTPases in invasion, motility, and matrix adhesion in inflammatory and aggressive breast cancers.
Cancer. 2010 Jun 1;116(11 Suppl):2768-82.

Ventura AC, Jiang P, Van Wassenhove L, Del Vecchio D, Merajver SD, Ninfa AJ.
Signaling properties of a covalent modification cycle are altered by a downstream target.
Proc Natl Acad Sci U S A. 2010 Jun 1;107(22):10032-7. Epub 2010 May 17.

Dey S, Hablas A, Seifeldin IA, Ismail K, Ramadan M, El-Hamzawy H, Wilson ML, Banerjee M, Boffetta P, Harford J, Merajver SD, Soliman AS.
Urban-rural differences of gynaecological malignancies in Egypt (1999-2002).
BJOG. 2010 Feb;117(3):348-55. Epub 2009 Dec 16.

Dey S, Soliman AS, Hablas A, Seifeldin IA, Ismail K, Ramadan M, El-Hamzawy H, Wilson ML, Banerjee M, Boffetta P, Harford J, Merajver SD.
Urban-rural differences in breast cancer incidence by hormone receptor status across 6 years in Egypt.
Breast Cancer Res Treat. 2010 Feb;120(1):149-60. Epub 2009 Jun 23.

Burson AM, Soliman AS, Ngoma TA, Mwaiselage J, Ogweyo P, Eissa MS, Dey S, Merajver SD.
Clinical and epidemiologic profile of breast cancer in Tanzania.
Breast Dis. 2010;31(1):33-41.

Iniesta MD, Chien J, Wicha M, Merajver SD.
One-hit effects and cancer.
Cancer Prev Res (Phila). 2010 Jan;3(1):12-5. Review.

Rosenthal DT, Iyer H, Escudero S, Ventura AC, Arruda EM, Garikipati K, Merajver SD.
From in vitro to in silico and back again: using biological and mathematical synergy to decipher breast cancer cell motility.
Conf Proc IEEE Eng Med Biol Soc. 2010;2010:3261-4.


Pan Q, Rosenthal DT, Bao L, Kleer CG, Merajver SD.
Antiangiogenic tetrathiomolybdate protects against Her2/neu-induced breast carcinoma by hypoplastic remodeling of the mammary gland.
Clin Cancer Res. 2009 Dec 1;15(23):7441-6. Epub 2009 Nov 24.

Iniesta MD, Mooney CJ, Merajver SD.
Inflammatory breast cancer: what are the treatment options?
Expert Opin Pharmacother. 2009 Dec;10(18):2987-97. Review.

Chang CW, Wu M, Merajver SD, Mycek MA.
Physiological fluorescence lifetime imaging microscopy improves Förster resonance energy transfer detection in living cells.
J Biomed Opt. 2009 Nov-Dec;14(6):060502.

Islam M, Lin G, Brenner JC, Pan Q, Merajver SD, Hou Y, Kumar P, Teknos TN.
RhoC expression and head and neck cancer metastasis.
Mol Cancer Res. 2009 Nov;7(11):1771-80. Epub 2009 Oct 27.

Li X, Gonzalez ME, Toy K, Filzen T, Merajver SD, Kleer CG.
Targeted overexpression of EZH2 in the mammary gland disrupts ductal morphogenesis and causes epithelial hyperplasia.
Am J Pathol. 2009 Sep;175(3):1246-54. Epub 2009 Aug 6.

Khan GN, Gorin MA, Rosenthal D, Pan Q, Bao LW, Wu ZF, Newman RA, Pawlus AD, Yang P, Lansky EP, Merajver SD.
Pomegranate fruit extract impairs invasion and motility in human breast cancer.
Integr Cancer Ther. 2009 Sep;8(3):242-53.

Bao L, Gorin MA, Zhang M, Ventura AC, Pomerantz WC, Merajver SD, Teknos TN, Mapp AK, Pan Q.
Preclinical development of a bifunctional cancer cell homing, PKCepsilon inhibitory peptide for the treatment of head and neck cancer.
Cancer Res. 2009 Jul 15;69(14):5829-34. Epub 2009 Jun 30.

Soliman AS, Banerjee M, Lo AC, Ismail K, Hablas A, Seifeldin IA, Ramadan M, Omar HG, Fokuda A, Harford JB, Merajver SD.
High proportion of inflammatory breast cancer in the Population-based Cancer Registry of Gharbiah, Egypt.
Breast J. 2009 Jul-Aug;15(4):432-4.

Dey S, Soliman AS, Merajver SD.
Xenoestrogens may be the cause of high and increasing rates of hormone receptor positive breast cancer in the world.
Med Hypotheses. 2009 Jun;72(6):652-6. Epub 2009 Jan 19.

Gartner EM, Griffith KA, Pan Q, Brewer GJ, Henja GF, Merajver SD, Zalupski MM.
A pilot trial of the anti-angiogenic copper lowering agent tetrathiomolybdate in combination with irinotecan, 5-flurouracil, and leucovorin for metastatic colorectal cancer.
Invest New Drugs. 2009 Apr;27(2):159-65. Epub 2008 Aug 20.

Hensley Alford S, Schwartz K, Soliman A, Johnson CC, Gruber SB, Merajver SD.
Breast cancer characteristics at diagnosis and survival among Arab-American women compared to European- and African-American women.
Breast Cancer Res Treat. 2009 Mar;114(2):339-46. Epub 2008 Apr 15.

Gonzalez ME, Li X, Toy K, DuPrie M, Ventura AC, Banerjee M, Ljungman M, Merajver SD, Kleer CG.
Downregulation of EZH2 decreases growth of estrogen receptor-negative invasive breast carcinoma and requires BRCA1.
Oncogene. 2009 Feb 12;28(6):843-53. Epub 2008 Dec 15.

Lo AC, Georgopoulos A, Kleer CG, Banerjee M, Omar S, Khaled H, Eissa S, Hablas A, Omar HG, Douglas JA, Merajver SD, Soliman AS.
Analysis of RhoC expression and lymphovascular emboli in inflammatory vs non-inflammatory breast cancers in Egyptian patients.
Breast. 2009 Feb;18(1):55-9. Epub 2009 Jan 20.

Ventura AC, Jackson TL, Merajver SD.
On the role of cell signaling models in cancer research.
Cancer Res. 2009 Jan 15;69(2):400-2. Review.

Wasielewski M, Hanifi-Moghaddam P, Hollestelle A, Merajver SD, van den Ouweland A, Klijn JG, Ethier SP, Schutte M.
Deleterious CHEK2 1100delC and L303X mutants identified among 38 human breast cancer cell lines.
Breast Cancer Res Treat. 2009 Jan;113(2):285-91. Epub 2008 Feb 24.


Houchens NW, Merajver SD.
Molecular determinants of the inflammatory breast cancer phenotype.
Oncology (Williston Park). 2008 Dec;22(14):1556-61; discussion 1561, 1565-8, 1576.

Lo AC, Kleer CG, Banerjee M, Omar S, Khaled H, Eissa S, Hablas A, Douglas JA, Alford SH, Merajver SD, Soliman AS.
Molecular epidemiologic features of inflammatory breast cancer: a comparison between Egyptian and US patients.
Breast Cancer Res Treat. 2008 Nov;112(1):141-7. Epub 2007 Dec 4.

Ho TT, Merajver SD, Lapière CM, Nusgens BV, Deroanne CF.
RhoA-GDP regulates RhoB protein stability. Potential involvement of RhoGDIalpha.
J Biol Chem. 2008 Aug 1;283(31):21588-98. Epub 2008 Jun 4.

Iniesta MD, Merajver SD.
CHEK2 screening: do not think so globally yet.
J Clin Oncol. 2008 Jun 20;26(18):3092; author reply 3093-4.

Huang W, Zhang Y, Varambally S, Chinnaiyan AM, Banerjee M, Merajver SD, Kleer CG.
Inhibition of CCN6 (Wnt-1-induced signaling protein 3) down-regulates E-cadherin in the breast epithelium through induction of snail and ZEB1.
Am J Pathol. 2008 Apr;172(4):893-904. Epub 2008 Mar 5.

Ventura AC, Sepulchre JA, Merajver SD.
A hidden feedback in signaling cascades is revealed.
PLoS Comput Biol. 2008 Mar 21;4(3):e1000041.

Liu S, Ginestier C, Charafe-Jauffret E, Foco H, Kleer CG, Merajver SD, Dontu G, Wicha MS.
BRCA1 regulates human mammary stem/progenitor cell fate.
Proc Natl Acad Sci U S A. 2008 Feb 5;105(5):1680-5. Epub 2008 Jan 29.

Ventura AC, Merajver SD.
Genetic determinants of aggressive breast cancer.
Annu Rev Med. 2008;59:199-212. Review.


Zhong W, Wu M, Chang CW, Merrick KA, Merajver SD, Mycek MA.
Picosecond-resolution fluorescence lifetime imaging microscopy: a useful tool for sensing molecular interactions in vivo via FRET.
Opt Express. 2007 Dec 24;15(26):18220-35.

Bevers TB, Armstrong DK, Arun B, Carlson RW, Cowan KH, Daly MB, Fleming I, Garber JE, Gemignani M, Gradishar WJ, Krontiras H, Kulkarni S, Laronga C, Lawton T, Loftus L, Macdonald DJ, Mahoney MC, Merajver SD, Seewaldt V, Sellin RV, Shapiro CL, Singletary E, Ward JH; National Comprehensive Cancer Network (NCCN).
Breast cancer risk reduction.
J Natl Compr Canc Netw. 2007 Sep;5(8):676-701.

Evelyn CR, Wade SM, Wang Q, Wu M, Iñiguez-Lluhí JA, Merajver SD, Neubig RR.
CCG-1423: a small-molecule inhibitor of RhoA transcriptional signaling.
Mol Cancer Ther. 2007 Aug;6(8):2249-60.

Hassouneh B, Islam M, Nagel T, Pan Q, Merajver SD, Teknos TN.
Tetrathiomolybdate promotes tumor necrosis and prevents distant metastases by suppressing angiogenesis in head and neck cancer.
Mol Cancer Ther. 2007 Mar;6(3):1039-45.

Wu M, Wu ZF, Merajver SD.
Rho proteins and cell-matrix interactions in cancer.
Cells Tissues Organs. 2007;185(1-3):100-3. Review.

Kleer CG, Zhang Y, Merajver SD.
CCN6 (WISP3) as a new regulator of the epithelial phenotype in breast cancer.
Cells Tissues Organs. 2007;185(1-3):95-9. Review.

Khan GN, Merajver SD.
Modulation of angiogenesis for cancer prevention: strategies based on antioxidants and copper deficiency.
Curr Pharm Des. 2007;13(35):3584-90. Review.


Pan Q, Bao LW, Teknos TN, Merajver SD.
Targeted disruption of protein kinase C epsilon reduces cell invasion and motility through inactivation of RhoA and RhoC GTPases in head and neck squamous cell carcinoma.
Cancer Res. 2006 Oct 1;66(19):9379-84.

Shah NM, Soliman AS, Benerjee M, Merajver SD, Ismail K, Seifeldin I, Hablas A, Zarzour A, Abdel-Aziz A, Ben Ayed F, Chamberlain RM.
Knowledge gained after a brief CME module on breast cancer diagnosis.
J Cancer Educ. 2006 Fall;21(3):169-74.

Kleer CG, Teknos TN, Islam M, Marcus B, Lee JS, Pan Q, Merajver SD.
RhoC GTPase expression as a potential marker of lymph node metastasis in squamous cell carcinomas of the head and neck.
Clin Cancer Res. 2006 Aug 1;12(15):4485-90.

Pierce LJ, Levin AM, Rebbeck TR, Ben-David MA, Friedman E, Solin LJ, Harris EE, Gaffney DK, Haffty BG, Dawson LA, Narod SA, Olivotto IA, Eisen A, Whelan TJ, Olopade OI, Isaacs C, Merajver SD, Wong JS, Garber JE, Weber BL.
Ten-year multi-institutional results of breast-conserving surgery and radiotherapy in BRCA1/2-associated stage I/II breast cancer.
J Clin Oncol. 2006 Jun 1;24(16):2437-43. Epub 2006 Apr 24.

Ding L, Erdmann C, Chinnaiyan AM, Merajver SD, Kleer CG.
Identification of EZH2 as a molecular marker for a precancerous state in morphologically normal breast tissues.
Cancer Res. 2006 Apr 15;66(8):4095-9.

Khan MK, Mamou F, Schipper MJ, May KS, Kwitny A, Warnat A, Bolton B, Nair BM, Kariapper MS, Miller M, Brewer G, Normolle D, Merajver SD, Teknos TN.
Combination tetrathiomolybdate and radiation therapy in a mouse model of head and neck squamous cell carcinoma.
Arch Otolaryngol Head Neck Surg. 2006 Mar;132(3):333-8.

Van den Eynden GG, Van Laere SJ, Van der Auwera I, Merajver SD, Van Marck EA, van Dam P, Vermeulen PB, Dirix LY, van Golen KL.
Overexpression of caveolin-1 and -2 in cell lines and in human samples of inflammatory breast cancer.
Breast Cancer Res Treat. 2006 Feb;95(3):219-28. Epub 2005 Oct 22.

Elstrodt F, Hollestelle A, Nagel JH, Gorin M, Wasielewski M, van den Ouweland A, Merajver SD, Ethier SP, Schutte M.
BRCA1 mutation analysis of 41 human breast cancer cell lines reveals three new deleterious mutants.
Cancer Res. 2006 Jan 1;66(1):41-5.


Goodman VL, Brewer GJ, Merajver SD.
Control of copper status for cancer therapy.
Curr Cancer Drug Targets. 2005 Nov;5(7):543-9. Review.

Zeidler M, Varambally S, Cao Q, Chinnaiyan AM, Ferguson DO, Merajver SD, Kleer CG.
The Polycomb group protein EZH2 impairs DNA repair in breast epithelial cells.
Neoplasia. 2005 Nov;7(11):1011-9.

Merajver SD, Usmani SZ.
Multifaceted role of Rho proteins in angiogenesis.
J Mammary Gland Biol Neoplasia. 2005 Oct;10(4):291-8. Review.

Pan Q, Bao LW, Kleer CG, Sabel MS, Griffith KA, Teknos TN, Merajver SD.
Protein kinase C epsilon is a predictive biomarker of aggressive breast cancer and a validated target for RNA interference anticancer therapy.
Cancer Res. 2005 Sep 15;65(18):8366-71.

Kleer CG, Griffith KA, Sabel MS, Gallagher G, van Golen KL, Wu ZF, Merajver SD.
RhoC-GTPase is a novel tissue biomarker associated with biologically aggressive carcinomas of the breast.
Breast Cancer Res Treat. 2005 Sep;93(2):101-10.

Lin M, DiVito MM, Merajver SD, Boyanapalli M, van Golen KL.
Regulation of pancreatic cancer cell migration and invasion by RhoC GTPase and caveolin-1.
Mol Cancer. 2005 Jun 21;4(1):21.

Wang C, Gonzalez R, Milliron KJ, Strecher VJ, Merajver SD.
Genetic counseling for BRCA1/2: a randomized controlled trial of two strategies to facilitate the education and counseling process.
Am J Med Genet A. 2005 Apr 1;134A(1):66-73.

Teknos TN, Islam M, Arenberg DA, Pan Q, Carskadon SL, Abarbanell AM, Marcus B, Paul S, Vandenberg CD, Carron M, Nor JE, Merajver SD.
The effect of tetrathiomolybdate on cytokine expression, angiogenesis, and tumor growth in squamous cell carcinoma of the head and neck.
Arch Otolaryngol Head Neck Surg. 2005 Mar;131(3):204-11.

Zhang Y, Pan Q, Zhong H, Merajver SD, Kleer CG.
Inhibition of CCN6 (WISP3) expression promotes neoplastic progression and enhances the effects of insulin-like growth factor-1 on breast epithelial cells.
Breast Cancer Res. 2005;7(6):R1080-9. Epub 2005 Nov 8.

Wu M, Merajver SD.
Molecular biology of inflammatory breast cancer: applications to diagnosis, prognosis, and therapy.
Breast Dis. 2005-2006;22:25-34. Review.


Marcus B, Arenberg D, Lee J, Kleer C, Chepeha DB, Schmalbach CE, Islam M, Paul S, Pan Q, Hanash S, Kuick R, Merajver SD, Teknos TN.
Prognostic factors in oral cavity and oropharyngeal squamous cell carcinoma.
Cancer. 2004 Dec 15;101(12):2779-87.

Goodman VL, Brewer GJ, Merajver SD.
Copper deficiency as an anti-cancer strategy.
Endocr Relat Cancer. 2004 Jun;11(2):255-63. Review.

Wang C, Gonzalez R, Merajver SD.
Assessment of genetic testing and related counseling services: current research and future directions.
Soc Sci Med. 2004 Apr;58(7):1427-42.

Wu M, Wu ZF, Kumar-Sinha C, Chinnaiyan A, Merajver SD.
RhoC induces differential expression of genes involved in invasion and metastasis in MCF10A breast cells.
Breast Cancer Res Treat. 2004 Mar;84(1):3-12.

Kleer CG, Zhang Y, Pan Q, Merajver SD.
WISP3 (CCN6) is a secreted tumor-suppressor protein that modulates IGF signaling in inflammatory breast cancer.
Neoplasia. 2004 Mar-Apr;6(2):179-85.

Kleer CG, Zhang Y, Pan Q, Gallagher G, Wu M, Wu ZF, Merajver SD.
WISP3 and RhoC guanosine triphosphatase cooperate in the development of inflammatory breast cancer.
Breast Cancer Res. 2004;6(2):R110-5.

Kleer CG, Zhang Y, Pan Q, Gallagher G, Wu M, Wu ZF, Merajver SD.
WISP3 and RhoC guanosine triphosphatase cooperate in the development of inflammatory breast cancer.
Breast Cancer Res. 2004;6(1):R110-5.


Collisson EA, Kleer C, Wu M, De A, Gambhir SS, Merajver SD, Kolodney MS.
Atorvastatin prevents RhoC isoprenylation, invasion, and metastasis in human melanoma cells.
Mol Cancer Ther. 2003 Oct;2(10):941-8.

Pan Q, Bao LW, Merajver SD.
Tetrathiomolybdate inhibits angiogenesis and metastasis through suppression of the NFkappaB signaling cascade.
Mol Cancer Res. 2003 Aug;1(10):701-6.

Cox C, Merajver SD, Yoo S, Dick RD, Brewer GJ, Lee JS, Teknos TN.
Inhibition of the growth of squamous cell carcinoma by tetrathiomolybdate-induced copper suppression in a murine model.
Arch Otolaryngol Head Neck Surg. 2003 Jul;129(7):781-5.

Pan Q, Bao LW, Kleer CG, Brewer GJ, Merajver SD.
Antiangiogenic tetrathiomolybdate enhances the efficacy of doxorubicin against breast carcinoma.
Mol Cancer Ther. 2003 Jul;2(7):617-22.

Redman BG, Esper P, Pan Q, Dunn RL, Hussain HK, Chenevert T, Brewer GJ, Merajver SD.
Phase II trial of tetrathiomolybdate in patients with advanced kidney cancer.
Clin Cancer Res. 2003 May;9(5):1666-72.

Merajver SD, Milliron K.
Breast cancer risk assessment: a guide for clinicians using the NCCN Breast Cancer Risk Reduction Guidelines.
J Natl Compr Canc Netw. 2003 Apr;1(2):297-301.


Brewer GJ, Merajver SD.
Cancer therapy with tetrathiomolybdate: antiangiogenesis by lowering body copper--a review.
Integr Cancer Ther. 2002 Dec;1(4):327-37. Review.

Pan Q, Kleer CG, van Golen KL, Irani J, Bottema KM, Bias C, De Carvalho M, Mesri EA, Robins DM, Dick RD, Brewer GJ, Merajver SD.
Copper deficiency induced by tetrathiomolybdate suppresses tumor growth and angiogenesis.
Cancer Res. 2002 Sep 1;62(17):4854-9.

van Golen KL, Bao L, Brewer GJ, Pienta KJ, Kamradt JM, Livant DL, Merajver SD.
Suppression of tumor recurrence and metastasis by a combination of the PHSCN sequence and the antiangiogenic compound tetrathiomolybdate in prostate carcinoma.
Neoplasia. 2002 Sep-Oct;4(5):373-9.

Kleer CG, Tseng MD, Gutsch DE, Rochford RA, Wu Z, Joynt LK, Helvie MA, Chang T, Van Golen KL, Merajver SD.
Detection of Epstein-Barr virus in rapidly growing fibroadenomas of the breast in immunosuppressed hosts.
Mod Pathol. 2002 Jul;15(7):759-64.

Munshi HG, Merajver SD, Valdez R, Baker LH, Cooney KA.
Metastatic dedifferentiated chordoma with elevated beta-hCG: a case report.
Am J Clin Oncol. 2002 Jun;25(3):274-6.

van Golen KL, Bao L, DiVito MM, Wu Z, Prendergast GC, Merajver SD.
Reversion of RhoC GTPase-induced inflammatory breast cancer phenotype by treatment with a farnesyl transferase inhibitor.
Mol Cancer Ther. 2002 Jun;1(8):575-83.

Kleer CG, Zhang Y, Pan Q, van Golen KL, Wu ZF, Livant D, Merajver SD.
WISP3 is a novel tumor suppressor gene of inflammatory breast cancer.
Oncogene. 2002 May 9;21(20):3172-80.

Khan MK, Miller MW, Taylor J, Gill NK, Dick RD, Van Golen K, Brewer GJ, Merajver SD.
Radiotherapy and antiangiogenic TM in lung cancer.
Neoplasia. 2002 Mar-Apr;4(2):164-70.

Kleer CG, van Golen KL, Zhang Y, Wu ZF, Rubin MA, Merajver SD.
Characterization of RhoC expression in benign and malignant breast disease: a potential new marker for small breast carcinomas with metastatic ability.
Am J Pathol. 2002 Feb;160(2):579-84.

Peterson EA, Milliron KJ, Lewis KE, Goold SD, Merajver SD.
Health insurance and discrimination concerns and BRCA1/2 testing in a clinic population.
Cancer Epidemiol Biomarkers Prev. 2002 Jan;11(1):79-87.

van Golen KL, Bao LW, Pan Q, Miller FR, Wu ZF, Merajver SD.
Mitogen activated protein kinase pathway is involved in RhoC GTPase induced motility, invasion and angiogenesis in inflammatory breast cancer.
Clin Exp Metastasis. 2002;19(4):301-11.


Trask PC, Paterson AG, Wang C, Hayasaka S, Milliron KJ, Blumberg LR, Gonzalez R, Murray S, Merajver SD.
Cancer-specific worry interference in women attending a breast and ovarian cancer risk evaluation program: impact on emotional distress and health functioning.
Psychooncology. 2001 Sep-Oct;10(5):349-60.

Kleer CG, van Golen KL, Braun T, Merajver SD.
Persistent E-cadherin expression in inflammatory breast cancer.
Mod Pathol. 2001 May;14(5):458-64.

Cox C, Teknos TN, Barrios M, Brewer GJ, Dick RD, Merajver SD.
The role of copper suppression as an antiangiogenic strategy in head and neck squamous cell carcinoma.
Laryngoscope. 2001 Apr;111(4 Pt 1):696-701.


van Golen KL, Wu ZF, Qiao XT, Bao LW, Merajver SD.
RhoC GTPase, a novel transforming oncogene for human mammary epithelial cells that partially recapitulates the inflammatory breast cancer phenotype.
Cancer Res. 2000 Oct 15;60(20):5832-8.

van Golen KL, Wu ZF, Qiao XT, Bao L, Merajver SD.
RhoC GTPase overexpression modulates induction of angiogenic factors in breast cells.
Neoplasia. 2000 Sep-Oct;2(5):418-25.

Kleer CG, van Golen KL, Merajver SD.
Molecular biology of breast cancer metastasis. Inflammatory breast cancer: clinical syndrome and molecular determinants.
Breast Cancer Res. 2000;2(6):423-9. Epub 2000 Jul 11. Review.

Brewer GJ, Dick RD, Grover DK, LeClaire V, Tseng M, Wicha M, Pienta K, Redman BG, Jahan T, Sondak VK, Strawderman M, LeCarpentier G, Merajver SD.
Treatment of metastatic cancer with tetrathiomolybdate, an anticopper, antiangiogenic agent: Phase I study.
Clin Cancer Res. 2000 Jan;6(1):1-10.


van Golen KL, Davies S, Wu ZF, Wang Y, Bucana CD, Root H, Chandrasekharappa S, Strawderman M, Ethier SP, Merajver SD.
A novel putative low-affinity insulin-like growth factor-binding protein, LIBC (lost in inflammatory breast cancer), and RhoC GTPase correlate with the inflammatory breast cancer phenotype.
Clin Cancer Res. 1999 Sep;5(9):2511-9.

van Golen K, Milliron K, Davies S, Merajver SD.
BRCA-associated cancer risk: molecular biology and clinical practice.
J Lab Clin Med. 1999 Jul;134(1):11-8. Review.


Merajver SD, Weber BL, Cody R, Zhang D, Strawderman M, Calzone KA, LeClaire V, Levin A, Irani J, Halvie M, August D, Wicha M, Lichter A, Pierce LJ.
Breast conservation and prolonged chemotherapy for locally advanced breast cancer: the University of Michigan experience.
J Clin Oncol. 1997 Aug;15(8):2873-81.

Helvie MA, Roubidoux MA, Weber BL, Merajver SD.
Mammography of breast carcinoma in women who have mutations of the breast cancer gene BRCA1: initial experience.
AJR Am J Roentgenol. 1997 Jun;168(6):1599-602.


Abel KJ, Brody LC, Valdes JM, Erdos MR, McKinley DR, Castilla LH, Merajver SD, Couch FJ, Friedman LS, Ostermeyer EA, Lynch ED, King MC, Welcsh PL, Osborne-Lawrence S, Spillman M, Bowcock AM, Collins FS, Weber BL.
Characterization of EZH1, a human homolog of Drosophila Enhancer of zeste near BRCA1.
Genomics. 1996 Oct 15;37(2):161-71.

Caduff RF, Johnston CM, Svoboda-Newman SM, Poy EL, Merajver SD, Frank TS.
Clinical and pathological significance of microsatellite instability in sporadic endometrial carcinoma.
Am J Pathol. 1996 May;148(5):1671-8.

Simon JS, Deshmukh G, Couch FJ, Merajver SD, Weber BL, Van Vooren P, Tissil F, Szpirer J, Szpirer C, Alper SL, Jacob HJ, Brosius FC 3rd.
Chromosomal mapping of the rat Slc4a family of anion exchanger genes, Ae1, Ae2, and Ae3.
Mamm Genome. 1996 May;7(5):380-2.

Cooney KA, Wetzel JC, Merajver SD, Macoska JA, Singleton TP, Wojno KJ.
Distinct regions of allelic loss on 13q in prostate cancer.
Cancer Res. 1996 Mar 1;56(5):1142-5.

Merajver SD, Petty EM.
Risk assessment and presymptomatic molecular diagnosis in hereditary breast cancer.
Clin Lab Med. 1996 Mar;16(1):139-67.

Helvie MA, Joynt LK, Cody RL, Pierce LJ, Adler DD, Merajver SD.
Locally advanced breast carcinoma: accuracy of mammography versus clinical examination in the prediction of residual disease after chemotherapy.
Radiology. 1996 Feb;198(2):327-32.


Merajver SD, Frank TS, Xu J, Pham TM, Calzone KA, Bennett-Baker P, Chamberlain J, Boyd J, Garber JE, Collins FS, et al.
Germline BRCA1 mutations and loss of the wild-type allele in tumors from families with early onset breast and ovarian cancer.
Clin Cancer Res. 1995 May;1(5):539-44.

Merajver SD, Pham TM, Caduff RF, Chen M, Poy EL, Cooney KA, Weber BL, Collins FS, Johnston C, Frank TS.
Somatic mutations in the BRCA1 gene in sporadic ovarian tumours.
Nat Genet. 1995 Apr;9(4):439-43.

Hoskins KF, Stopfer JE, Calzone KA, Merajver SD, Rebbeck TR, Garber JE, Weber BL.
Assessment and counseling for women with a family history of breast cancer. A guide for clinicians.
JAMA. 1995 Feb 15;273(7):577-85.

Couch FJ, Garber J, Kiousis S, Calzone K, Hauser ER, Merajver SD, Frank TS, Boehnke M, Chamberlain JS, Collins FS, et al.
Genetic analysis of eight breast-ovarian cancer families with suspected BRCA1 mutations.
J Natl Cancer Inst Monogr. 1995;(17):9-14.


Weber BL, Abel KJ, Brody LC, Flejter WL, Chandrasekharappa SC, Couch FJ, Merajver SD, Collins FS.
Familial breast cancer. Approaching the isolation of a susceptibility gene.
Cancer. 1994 Aug 1;74(3 Suppl):1013-20. Review.

Weber BL, Abel KJ, Couch FJ, Merajver SD, Chandrasekharappa SC, Castilla L, McKinley D, Ho PP, Calzone K, Frank TS, et al.
Progress toward isolation of a breast cancer susceptibility gene, BRCA1.
Cold Spring Harb Symp Quant Biol. 1994;59:531-6.


Kikuchi GE, Baker SA, Merajver SD, Coligan JE, Levine M, Glorioso JC, Nairn R.
Purification and structural characterization of herpes simplex virus glycoprotein C.
Biochemistry. 1987 Jan 27;26(2):424-31.


Merajver SD, Sheridan JP, Siguel EN.
Theory of the conformational order of single component sphingomyelin bilayers.
J Theor Biol. 1981 Dec 21;93(4):737-55.